Objective To develop a novel drug lymphocyte stimulation test( DLST) using cell counting kit- 8( CCK- 8) assay,and to investigate its application in the diagnosis of acute drug- induced liver injury( DILI). Methods The patients with acute DILI who were admitted to Beijing You An Hospital from January 2011 to December 2014 were screened,and the suspected drugs for liver injury were collected. The patients' peripheral blood mononuclear cells( PBMCs) were isolated,cultured in vitro,and then incubated with the suspected drugs. The CCK- 8 assay was used to measure the proliferation of lymphocytes. A positive control group was established for each experiment and was stimulated by phytohemagglutinin. Meanwhile,PBMCs from healthy subjects were enrolled as the negative control group,and were exposed to the same drugs and measured simultaneously. The results of DLST were introduced into the Roussel Uclaf Causality Assessment Method( RUCAM) scoring system to assess their effects on the sensitivity of the diagnosis of acute DILI. The chi- square test was used for comparison of categorical data between groups. Results Preliminary experiments were performed to determine the experimental conditions of DLST based on CCK- 8 assay. A total of 61 patients with acute DILI were enrolled. DLST based on CCK- 8 assay was completed in 52 patients who received a total of 75 drugs,and the results were identified to be reliable in 48 patients with 70 drugs. A total of 19 patients with22 drugs achieved positive results of DLST,with positive rates of patients and drugs being 39. 6% and 31. 4%,respectively,and a specificity of 93. 8%. Thirteen( 38. 2%) out of 34 traditional Chinese medicines and 9( 25%) out of 36 Western medicines achieved positive results of DLST,and the median stimulation index was 2. 29( 1. 81- 14. 20). After the results of DLST were introduced into the RUCAM scoring system,the proportion of drugs assessed as“highly probable”or “probable”were increased from 74. 7% to 92. 0%( χ2= 8. 112,P =0. 004). Conclusion CCK- 8 assay can be used to perform DLST,and the introduction of DLST results into the RUCAM scoring system can significantly improve the sensitivity of RUCAM in the diagnosis of DILI. Compared with the conventional DLST,DLST based on CCK-8 has the advantages of few requirements for laboratories,a simple and timesaving procedure,and low costs,and can be further used and verified in clinical practice.
[1]WATANABE M,SHIBUYA A.Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales[J].Hepatol Res,2004,30(3):148-154.
|
[2]Collaborative Group of Hepatobiliary Disease of Digestive Disease Branch of Chinese Medical Association.Recommendation of management for drug induced acute liver injury(Protocal)[J].Chin J Dig,2007,27(11):765-767.(in Chinese)中华医学会消化病学分会肝胆疾病协作组.急性药物性肝损伤诊治建议(草案)[J].中华消化杂志,2007,27(11):765-767.
|
[3]DANAN G,BENICHOU C.Causality assessment of adverse reactions to drugs—I.A novel method based on the conclusions of international consensus meetings:application to drug-induced liver injuries[J].J Clin Epidemiol,1993,46(11):1323-1330.
|
[4]HAO KY,YU YC,HE CL.RUCAM sacle-based diagnosis,clinical features and prognosis of 140 cases of drug-induced liver injury[J].Chin J Hepatol,2014,22(12):938-941.(in Chinese)郝坤艳,于乐成,何长伦.基于Roussel uclaf因果关系评估量表的药物性肝损伤140例诊治分析[J].中华肝脏病杂志,2014,22(12):938-941.
|
[5]TAKIKAWA H,TAKAMORI Y,KUMAGI T,et al.Assessment of 287Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting[J].Hepatol Res,2003,27(3):192-195.
|
[6]USUI K,ODA Y,KUBOTA R,et al.Clinical application of the leukocyte migration test and new diagnostic criteria for identifying causative agents in patients with drug-induced liver injury[J].Hepatogastroenterology,2007,54(78):1752-1757.
|
[7]MURATA H,SHIMIZU Y,OKADA K,et al.Detection and analysis of intracytoplasmic cytokines in peripheral blood mononuclear cells in patients with drug induced liver injury[J].J Hepatol,2003,38(5):573-582.
|
[8]CHALASANI NP,HAYASHI PH,BONKOVSKY HL,et al.ACG clinical guideline:the diagnosis and management of idiosyncratic drug-induced liver injury[J].Am J Gastroenterol,2014,109(7):950-966.
|
[9]CHEN GY,CHEN CW,FU QC.Set up drug lymphocyte stimulation test(3H-TdR)and observe it's application in drug-induced liver injury[J].Chin J Hepatol,2012,20(3):190-192.(in Chinese)陈高艳,陈成伟,傅青春.药物淋巴细胞刺激试验及其在药物性肝病诊断中的应用[J].中华肝脏病杂志,2012,20(3):190-192.
|
[10]SUN SS,FU QC,YANG J.The efficacy of drug lymphocyte stimulation test in diagnosis of drug-induced liver injury[J].Chin Hepatol,2015,20(3):215-217.(in Chinese)孙双双,傅青春,杨峻.药物淋巴细胞刺激试验在药物性肝损伤诊断中的意义[J].肝脏,2015,20(3):215-217.
|
[1] | Ruitao YANG, Rui YANG, Xun DENG, Senxiang ZENG, Xiaoyan YANG. Diagnosis and treatment principles of liver injury induced by antithyroid drugs[J]. Journal of Clinical Hepatology, 2024, 40(3): 621-625. doi: 10.12449/JCH240331 |
[2] | Guojing XING, Longlong LUO, Lifei WANG, Shunna WANG, Xiaofeng ZHENG, Lixia LU, Jiucong ZHANG. Role of mesenchymal stem cells and their exosomes in the treatment of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(3): 633-638. doi: 10.12449/JCH240333 |
[3] | Rui CHEN, Zhixin WANG, Haining FAN, Haijiu WANG. Research advances in the role of lymphocyte activation gene-3 in liver-related diseases[J]. Journal of Clinical Hepatology, 2021, 37(4): 977-981. doi: 10.3969/j.issn.1001-5256.2021.04.056 |
[4] | Hou JunXing, Yan FenQin, Yu YueCheng. The pathogenesis,diagnosis,and treatment of drug-induced liver injury with extrahepatic adverse drug reactions[J]. Journal of Clinical Hepatology, 2020, 36(3): 497-500. doi: 10.3969/j.issn.1001-5256.2020.03.003 |
[5] | Jing Jing, He TingTing, Wang RuiLin, Zhang Fan, Niu Ming, Guo YuMing, Zhu Yun, Xiao XiaoHe, Wang JiaBo. Detection of the risk signals of drug-induced liver injury: Challenges and advances[J]. Journal of Clinical Hepatology, 2020, 36(3): 491-496. doi: 10.3969/j.issn.1001-5256.2020.03.002 |
[6] | Huang Ang, Sun Ying, Zou ZhengSheng. Recent research advances in chronicity of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(3): 501-504. doi: 10.3969/j.issn.1001-5256.2020.03.004 |
[7] | Xiao XiaoHe. Combination of medicine and pharmacy assists for precise prevention and control of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(3): 489-490. doi: 10.3969/j.issn.1001-5256.2020.03.001 |
[8] | Yang Xue, Tu RongFang, Yang JinHui. Research advances in drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(3): 509-513. doi: 10.3969/j.issn.1001-5256.2020.03.006 |
[9] | Ye LiHong, Wang ChongKui, Shao Chen, Zhang HaiCong, Liu ZhiQuan, Wang TaiLing. Clinical and biochemical features of bile duct injury type of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(5): 1059-1064. doi: 10.3969/j.issn.1001-5256.2020.05.022 |
[10] | Liu Meng, Yang XuanZi, Yu LeCheng. Current status of the pathogenesis, diagnosis, and treatment of drug-induced cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(2): 252-257. doi: 10.3969/j.issn.1001-5256.2019.02.003 |
[11] | Han Ying, Chen Jie, Dan Jing, Liu YanMin, Zhang XiaoDan, Ren MeiXin, Du XiaoFei, Bian XinQu, Liu Dan, Huang YunLi, Huang ChunYang, Liao HuiYu. Value of fumarate hydratase antibody in differential diagnosis of autoimmune hepatitis and drug-induced liver injury[J]. Journal of Clinical Hepatology, 2019, 35(6): 1326-1329. doi: 10.3969/j.issn.1001-5256.2019.06.029 |
[12] | Kong XiaoLu, Shao Xue, Li DongFu. Senile intestinal lymphangiectasia with drug-induced liver injury: A case report[J]. Journal of Clinical Hepatology, 2019, 35(8): 1800-1802. doi: 10.3969/j.issn.1001-5256.2019.08.030 |
[13] | Bian ZhaoLian, Shao JianGuo, Ma Xiong. Differential diagnosis of drug-induced liver injury and autoimmune hepatitis and related therapeutic strategies[J]. Journal of Clinical Hepatology, 2018, 34(6): 1156-1159. doi: 10.3969/j.issn.1001-5256.2018.06.003 |
[14] | Yu LeCheng, Fan Ye, Chen ChengWei. Diagnosis and treatment of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2018, 34(6): 1160-1165. doi: 10.3969/j.issn.1001-5256.2018.06.004 |
[15] | Chou LiXia, Fan ZuoPeng, Liu Ying, Liang Shan, Nie Wei, Lin Wei, Liu YiRong, Zhang Jing, Hu ZhongJie. Application of a modified diagnostic scale in diagnosis of acute drug-induced liver injury[J]. Journal of Clinical Hepatology, 2017, 33(7): 1328-1331. doi: 10.3969/j.issn.1001-5256.2017.07.025 |
[16] | Ji ChenHua, Zhang ZhuQing, Wang XiaoYuan, Lu ShuMing. Clinical features of elderly patients with drug-induced liver injury[J]. Journal of Clinical Hepatology, 2017, 33(3): 502-506. doi: 10.3969/j.issn.1001-5256.2017.03.021 |
[17] | Zhang Dong, Zhang Tao, Wu YuNan, Sun KeWei. A systematic analysis of the application of diagnostic criteria for drug-induced liver injury in China based on the literature[J]. Journal of Clinical Hepatology, 2017, 33(5): 919-923. doi: 10.3969/j.issn.1001-5256.2017.05.026 |
[18] | Yuan Ling, Yang YongGeng, Shen YouXiu, Ma YingCai. Research advances in drug- induced liver injury[J]. Journal of Clinical Hepatology, 2017, 33(2): 375-378. doi: 10.3969/j.issn.1001-5256.2017.02.038 |
[19] | Yu YueCheng, Fan Ye. Advances in Roussel Uclaf Causality Assessment Method for diagnosis of drug-induced liver injury and its comparison with structured expert opinion process[J]. Journal of Clinical Hepatology, 2016, 32(9): 1706-1713. doi: 10.3969/j.issn.1001-5256.2016.09.014 |
[20] | Lu Yi, Yu Hui. Discussion on idiosyncratic drug-induced liver injury in children[J]. Journal of Clinical Hepatology, 2015, 31(8): 1215-1217. doi: 10.3969/j.issn.1001-5256.2015.08.008 |
1. | 殷东杰,薛梦恒,杨过,黄永康,易阳,王宏勋,王丽梅. 芡实壳醇提物抑制人胃癌SGC7901细胞和人肝癌HepG2细胞增殖并促进其凋亡. 现代食品科技. 2022(06): 55-65 . ![]() | |
2. | 张睿. 糖皮质激素对高胆红素血症合并急性药物性肝损伤患者肝功能及血清学研究. 检验医学与临床. 2018(04): 563-565 . ![]() | |
3. | 齐正. 还原型谷胱甘肽联合复方甘草酸苷治疗药物性肝损伤疗效观察. 中国疗养医学. 2018(03): 310-311 . ![]() | |
4. | 吴于青,代亮,陈雪花,廖永美. 药物淋巴细胞刺激试验诊断抗结核药物所致超敏反应的临床价值研究. 中国全科医学. 2018(27): 3339-3342 . ![]() | |
5. | 赵欣,张娟. 异甘草酸镁注射液对高胆红素血症ADILI患者肝功能及血清学指标的影响. 临床医学研究与实践. 2018(28): 46-47 . ![]() | |
6. | 仇丽霞,范作鹏,刘颖,梁珊,聂巍,林伟,刘义荣,张晶,胡中杰. 一种改良诊断量表在急性药物性肝损伤诊断中的应用. 临床肝胆病杂志. 2017(07): 1328-1331 . ![]() |